Terms used in this chapter mean:
- (1) "Compounding," the constitution, reconstitution, combination, dilution, or another process causing a change in the form, composition, or strength of any ingredient or any other attribute of a product;
- (2) "Hazardous drug," a pharmaceutical that is antineoplastic, carcinogenic, mutagenic, or teratogenic;
- (3) “Nonsterile compounding," the process of combining, admixing, diluting, pooling, reconstituting other than as provided in the manufacturer's labeling, or otherwise altering a drug or bulk drug substance to create a non-sterile preparation; and
- (4) "Sterile compounding," the aseptic processing of any pharmaceutical preparation that is required to be sterile when administered to patients.
Source: 36 SDR 100, effective December 14, 2009 ; 50 SDR 138, effective June 2, 2024 .
General Authority: SDCL 36-11-11 (1)(3).
Law Implemented: SDCL 36-11- 2.2 (3) .
Prior versions effective: 2009-12-14.